Bukwang Pharm says real-world study links Latuda switch to 2.06 kg mean weight loss in bipolar patients

• Bukwang Pharm reported a real-world study showing patients switching to Latuda saw weight loss with improved depressive symptoms.
• Results were accepted for publication in BMC Psychiatry, marking formal disclosure rather than a future conference presentation.
• Patients’ psychiatric symptoms did not worsen during follow-up, supporting switching as a practical option for weight-related tolerability issues.
• Safety findings were broadly consistent with routine use, with no major treatment-limiting events reported in the study period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bukwang Pharm. Co. Ltd. published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.